









Markets
/
Stocks
/
nasdaq-cort
/

Corcept Therapeutics Inc

CORT

73.960USD

-14.400-16.30%

Close 10/10, 16:00（ET）Quotes delayed by 15 min

7.79BMarket Cap

58.26P/E TTM



Corcept Therapeutics Inc

73.960

-14.400-16.30%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Corcept Therapeutics Inc

Currency: USD Updated: 2025-10-09

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered undervalued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Corcept Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

34 / 173

Overall Ranking

97 / 4699

Industry

Pharmaceuticals

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 4 analysts

Buy

Current Rating

135.250

Target Price

+52.95%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Corcept Therapeutics Inc Highlights

StrengthsRisks

Corcept Therapeutics Incorporated is a commercial-stage company, which is engaged in the discovery and development of medications to treat severe endocrine, oncologic, metabolic and neurological disorders by modulating the effects of the hormone cortisol. The Company operates through the discovery, development and commercialization of the pharmaceutical products segment. The Company has marketed Korlym (mifepristone) in the United States for the treatment of patients suffering from Cushings syndrome. The Company’s portfolio of selective cortisol modulators consists of four series totaling approximately 1,000 compounds. Its portfolio of selective cortisol modulators consists of relacorilant, exicorilant, dazucorilant and miricorilant. Korlyms active ingredient, mifepristone, reduces the binding of excess cortisol to the GR, it can modulate the effects of abnormal levels and release patterns of cortisol without compromising cortisols healthy functions and rhythms.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 67.98% year-on-year.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 39.23.

Overvalued

The company’s latest PE is 68.58, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 80.09M shares, decreasing 13.00% quarter-over-quarter.

Held by John Hussman

Star Investor John Hussman holds 42.00K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.34.

Financial Health

Currency: USD Updated: 2025-10-09

The company's current financial score is 8.93, which is higher than the Pharmaceuticals industry's average of 7.77. Its financial status is robust, and its operating efficiency is high. Its latest quarterly revenue reached 194.43M, representing a year-over-year increase of 18.70%, while its net profit experienced a year-over-year increase of 0.96%.

Score

Industry at a Glance

Previous score

8.93

Change



Financials

9.37

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

8.37

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

10.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

9.17

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.76

Key Metrics

Free cash flow

No Data

Corcept Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-10-09

The company’s current valuation score is 4.51, which is lower than the Pharmaceuticals industry's average of 7.19. Its current P/E ratio is 68.58, which is 28.60% below the recent high of 88.19 and 29.92% above the recent low of 48.06.

Score

Industry at a Glance

Previous score

4.51

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 34/173

No Data

Earnings Forecast

Currency: USD Updated: 2025-10-09

The company’s current earnings forecast score is 8.00, which is higher than the Pharmaceuticals industry's average of 7.78. The average price target for Corcept Therapeutics Inc is 137.50, with a high of 145.00 and a low of 121.00.

Score

Industry at a Glance

Previous score

8.00

Change

Support & Resistance

No Data

Analyst Rating

Based on 4 analysts

Buy

Current Rating

135.250

Target Price

+53.07%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

182

Total

Median

Average

Company name

Ratings

Analysts

Corcept Therapeutics Inc

CORT

Biogen Inc

BIIB

Amgen Inc

AMGN

Vertex Pharmaceuticals Inc

VRTX

Eli Lilly and Co

LLY

AbbVie Inc

ABBV

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-10-09

The company’s current price momentum score is 9.59, which is higher than the Pharmaceuticals industry's average of 7.09. Sideways: Currently, the stock price is trading between the resistance level at 96.56 and the support level at 74.59, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

9.59

Change

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(0)

Indicators

Value

Direction

MACD(12,26,9)

-1.317

Neutral

RSI(14)

38.249

Neutral

STOCH(KDJ)(9,3,3)

39.738

Sell

ATR(14)

3.641

Low Volatility

CCI(14)

-176.159

Sell

Williams %R

95.302

Oversold

TRIX(12,20)

0.809

Sell

StochRSI(14)

0.000

Oversold

Moving Average

Sell(4)

Neutral(0)

Buy(2)

Indicators

Value

Direction

MA5

86.184

Sell

MA10

85.581

Sell

MA20

82.296

Sell

MA50

75.557

Sell

MA100

73.731

Buy

MA200

68.888

Buy

Institutional Confidence

Currency: USD Updated: 2025-10-09

The company’s current institutional recognition score is 7.00, which is higher than the Pharmaceuticals industry's average of 5.59. The latest institutional shareholding proportion is 76.01%, representing a quarter-over-quarter decrease of 17.35%. The largest institutional shareholder is The Vanguard, holding a total of 9.66M shares, representing 9.17% of shares outstanding, with 4.85% decrease in holdings.

Score

Industry at a Glance

Previous score

7.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

BlackRock Institutional Trust Company, N.A.

11.31M

-13.12%

The Vanguard Group, Inc.

Star Investors

9.66M

-3.03%

Ingalls & Snyder LLC (Asset Management)

7.72M

-0.25%

Renaissance Technologies LLC

Star Investors

6.27M

+2.01%

Baker (George Leonard Jr.)

5.31M

Parallel Advisors, LLC

3.87M

-2.55%

Belanoff (Joseph K)

2.98M

-0.02%

State Street Global Advisors (US)

2.97M

-12.77%

Wilson (James N)

2.35M

+5.82%

Dimensional Fund Advisors, L.P.

2.09M

-2.39%

Risk Assessment

Currency: USD Updated: 2025-10-09

The company’s current risk assessment score is 6.54, which is higher than the Pharmaceuticals industry's average of 5.11. The company's beta value is 0.44. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.